256 related articles for article (PubMed ID: 11039660)
1. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
2. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
4. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
5. Treatment of adult myelodysplastic syndromes.
Hellström-Lindberg E
Int J Hematol; 1999 Oct; 70(3):141-54. PubMed ID: 10561906
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
7. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
11. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
14. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
[TBL] [Abstract][Full Text] [Related]
15. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
16. Treatment with growth factors in myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Pathol Biol (Paris); 1997 Oct; 45(8):656-67. PubMed ID: 9569932
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
18. How to treat MDS without stem cell transplantation.
Gattermann N
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S30-6. PubMed ID: 19857591
[TBL] [Abstract][Full Text] [Related]
19. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
20. [The myelodysplastic syndrome II. New therapeutic principles, course and prognosis].
Hasselbalch HC; Juhl BR; Hansen PB
Ugeskr Laeger; 2002 Jan; 164(4):479-82. PubMed ID: 11838418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]